In this interview, we sat down with James Burt, CEO of Pharmanovia, to reflect on industry trends from 2024 and discuss the future of Value-Added Medicines (VAMs). From the company’s strategic expansion into the Asia-Pacific region to emerging trends in patient-centric innovations and sustainability, Burt shares his insights on what lies ahead for the pharmaceutical industry and how Pharmanovia is positioning itself to make a meaningful impact.
Moe: What industry trend do you see having a greater impact this year?
The continued shift towards sustainability in pharmaceutical manufacturing will be a major trend for the year. Regulatory bodies and stakeholders are emphasizing eco-friendly practices, and we’re actively exploring ways to reduce waste and optimize production efficiency. Additionally, personalized medicine is gaining traction, and VAMs can play a crucial role in tailoring treatments to meet individual patient needs more effectively.
Moe: How do you see the Value-Added Medicines (VAMs) space evolving in 2025?
The VAMs sector is becoming increasingly vital as healthcare systems look for innovative ways to improve existing medicines. In 2025, I anticipate an even stronger focus on patient-centric solutions, such as advanced drug formulations that can help enhance adherence and outcomes. Digital health integration will also play a bigger role, enabling better patient monitoring and support. Ultimately, VAMs will continue to bridge the gap between innovation and accessibility, ensuring patients receive the most effective treatments available.
Moe: You recently expanded your portfolio offering in APAC with the addition of a novel medicine, what are the immediate unmet needs that you aim to address?
Asia, particularly China, has a rapidly aging population, with approx. 50% of people aged 50 and above1, who are at risk of osteoporosis. Recognizing this demographic shift and the significant unmet medical needs, Pharmanovia is committed to supporting patients and healthcare professionals by introducing novel therapies that can help improve treatment outcomes and accessibility in the region. By leveraging our expertise in lifecycle management and market access, our aim is to drive innovation in healthcare across the globe, particularly in regions where we could deliver the largest benefits.
Moe: How does the in-licensing of this novel osteoporosis product align with Pharmanovia’s broader strategic goals?
Our strategy has evolved from acquiring legacy brands to becoming a platform for launching novel products. We now have a number of examples of transactions, such as the recently signed arrangement concerning Abaloparatide, where we will take products through registration and into clinical practice in key markets like China. This aligns with our goal of transitioning into a true specialty pharma company. By leveraging our expertise in life cycle management and market access, we are well-positioned to significantly impact global healthcare, particularly in regions with high unmet needs.
Moe: How do you plan to differentiate this new product in the APAC osteoporosis market to ensure successful adoption among healthcare providers and patients?
Scientifically, we have strong clinical data, particularly in hip fracture prevention, which is a significant concern given the aging population in China. Commercially, we have a robust promotional capability in China, with around 600 full time equivalent medical representatives. Given China’s unique healthcare landscape, we’re also leveraging online platforms to reach and educate potential patients and prescribers. This multi-faceted approach positions Pharmanovia as a key partner in both treatment provision and addressing the broader issue of osteoporosis awareness and treatment adherence in the region.
Moe: Taking geopolitical risks into consideration for strategic partnerships across the globe, what logistical advice would you give to companies looking to broaden their portfolios?
Building an agile supply chain is important to ensure supply chain resilience for global markets. Implementing strategies and collaborative foresight with partners across regions using late-stage differentiation and inventory maintenance is important for risk mitigation. While geopolitical tensions are a concern, healthcare products often enjoy more free trade due to ethical considerations. By having a flexible and resilient supply chain, we can ensure that patients have access to treatment without disruption, even in the face of potential trade disputes.
Moe: From an industry perspective, what’s one thing you’re looking forward to this year?
I’m particularly excited about the potential of strategic collaborations that have not existed before. Partnerships between pharmaceutical companies, tech innovators, and healthcare providers will drive meaningful progress in the industry. Our partnership to introduce a novel osteoporosis treatment in Asia is just the beginning – there’s immense potential to expand these efforts across multiple therapeutic areas. I’m looking forward to seeing how these collaborations can transform patient care and improve healthcare outcomes worldwide.
Moe: What advice would you give to companies looking to make a meaningful impact in the VAMs space?
Companies must prioritize innovation that aligns with patient needs while also fostering strong partnerships across the healthcare ecosystem. It’s essential to remain agile and responsive to regulatory changes, as well as to invest in digital health tools that support treatment adherence and long-term health outcomes. By combining scientific excellence with a patient-first approach, the outlook for the year ahead looks promising and I’m excited to see what’s to come.
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
